ORIGINAL_ARTICLE
AOJNMB appreciates the best contributors in years 2013-2015.
AOJNMB is striving for excellence. Our journal is publishing its 4th volume of publication and we are delighted to observe on time publication of this journal with important scientific articles. On November 2015, 11th Asia Oceania Congress of Nuclear Medicine & Biology (AOCNMB) was held in Jeju International Convention Center (JICC) in Korea with hundreds of participants and the abstracts of the meeting were published as a supplement issue of the AOJNMB (1). The 11th AOCNMB meeting was a great opportunity for me to thank the best contributors of the AOJNMB in the last three years. Actually, AOJNMB awarded three contributors for their invaluable effort in years 2013-2015. Prof. Seigo Kinuya was awarded as our “Best Associate Editor” for the highest number of successful editorship, Prof.Henry Bom as “Top Contributor” with the highest number of reviewed articles and Prof.Jerry Obaldo as the “Best Reviewer” for his rapid, critical and instructive reviews.
https://aojnmb.mums.ac.ir/article_6233_3e6065fc38bf0b7be198560a1a09a94c.pdf
2016-01-01
1
2
AOJNMB
Award
Reviewer
Contributor
Seyed Rasoul
Zakavi
zakavir@mums.ac.ir
1
Nuclear Medicine Research Center, Mashhad University of Medical Sciences
LEAD_AUTHOR
1. Abstracts, 11th Asia Oceania Congress of Nuclear Medicine and Biology; 54th Annual Autumn Meeting of the Korean Society of Nuclear Medicine; 14th Annual General Meeting of Asian Regional Cooperative Council for Nuclear Medicine, Jeju Korea. Asia Oceania J Nucl Med Biol. 2015; 3:(supp1):1-224.
1
2. Zakavi SR. AOJNMB changed its publication date; New Year, New Issue! Asia Oceania J Nucl Med Biol. 2015;3(1):1-2.
2
ORIGINAL_ARTICLE
Predictive ability of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for pathological complete response and prognosis after neoadjuvant chemotherapy in triple-negative breast cancer patients
Objective The mortality of patients with locally advanced triple-negative breast cancer (TNBC) is high, and pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) is associated with improved prognosis. This retrospective study was designed and powered to investigate the ability of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) to predict pathological response to NAC and prognosis after NAC.Methods The data of 32 consecutive women with clinical stage II or III TNBC from January 2006 to December 2013 in our institution who underwent FDG-PET/CT at baseline and after NAC were retrospectively analyzed. The maximum standardized uptake value (SUVmax) in the primary tumor at each examination and the change in SUVmax (ΔSUVmax) between the two scans were measured. Correlations between PET parameters and pathological response, and correlations between PET parameters and disease-free survival (DFS) were examined.Results At the completion of NAC, surgery showed pCR in 7 patients, while 25 had residual tumor, so-called non-pCR. Median follow-up was 39.0 months. Of the non-pCR patients, 9 relapsed at 3 years. Of all assessed clinical, biological, and PET parameters, N-stage, clinical stage, and ΔSUVmax were predictors of pathological response (p=0.0288, 0.0068, 0.0068; Fischer’s exact test). The cut-off value of ΔSUVmax to differentiate pCR evaluated by the receiver operating characteristic (ROC) curve analysis was 81.3%. Three-year disease-free survival (DFS) was lower in patients with non-pCR than in patients with pCR (p=0.328, log-rank test). The cut-off value of ΔSUVmax to differentiate 3-year DFS evaluated by the ROC analysis was 15.9%. In all cases, 3-year DFS was lower in patients with ΔSUVmax <15.9% than in patients with ΔSUVmax ≥15.9% (p=0.0078, log-rank test). In non-pCR patients, 3-year DFS was lower in patients with ΔSUVmax <15.9% than in patients with ΔSUVmax ≥15.9% (p=0.0238, log-rank test).Conclusions FDG-PET/CT at baseline and after NAC could predict pathological response to NAC before surgery and the clinical outcome after surgery in locally advanced TNBC patients.
https://aojnmb.mums.ac.ir/article_5619_838a952262d120f16258f657f7ef2bec.pdf
2016-01-01
3
11
10.7508/aojnmb.2016.04.002
FDG-PET/CT
Triple negative breast cancer
Neoadjuvant chemotherapy
Metabolic response
Prognosis
Sachiko
Kiyoto
skiyoto@shikoku-cc.go.jp
1
Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
LEAD_AUTHOR
Yoshifumi
Sugawara
ysugawara@shikoku-cc.go.jp
2
Department of Diagnostic Radiology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
AUTHOR
Kohei
Hosokawa
kohosokawa@shikoku-cc.go.jp
3
Department of Diagnostic Radiology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
AUTHOR
Rieko
Nishimura
rnishimu@shikoku-cc.go.jp
4
Department of Clinical Laboratory, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
AUTHOR
Natsumi
Yamashita
nayamashita@shikoku-cc.go.jp
5
Section of Cancer Prevention and Epidemiology, Clinical Research Center, National Hospital Organization Shikoku
Cancer Center, Matsuyama, Japan
AUTHOR
Shozo
Ohsumi
sosumi@shikoku-cc.go.jp
6
Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
AUTHOR
Teruhito
Mochizuki
tmochi@m.ehime-u.ac.jp
7
Department of Radiology, Ehime University, Matsuyama, Japan
AUTHOR
1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48.
1
2. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23(Suppl 6):vi7-12.
2
3. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2012;26(8):1275-81.
3
4. Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796-804.
4
5. Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomog-raphy compared with conventional imaging procedures. J Clin Oncol. 2008;26(29):4746-51.
5
6. Groheux D, Hindié E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, et al. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;104(24):1879-87.
6
7. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F] fluorodeoxyglucose.J Clin Oncol. 2009;27(4):535-41.
7
8. Groheux D, Giacchetti S, Espié M, Rubello D, Moretti JL, Hindié E. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging. 2011;38(3):419-25.
8
9. Nakajima N, Sugawara Y, Kataoka M, Hamamoto Y, Ochi T, Sakai S, et al. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings. Ann Nucl Med. 2013;27(3):261-70.
9
10. Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, et al. Early assessment with 18F-fluorodeoxyglucose positron emission tomography /computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. Eur J Cancer. 2014; 50(11): 1864-71.
10
11. Nagao T, Kinoshita T, Hojo T, Tsuda H, Tamura K, Fujiwara Y. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast. 2012;21(3):289-95.
11
12. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-72.
12
13. Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, et al.Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2015;42(3):377-85.
13
14. Groheux D, Hindié E, Giacchetti S, Delord M, Hamy AS, de Roquancourt A, et al. Triple-negative breast cancer: early assessment with 18F-FDG PET/ CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med. 2012;53(2):249-54.
14
15. Von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto). Ann Oncol. 2014;25(12):2363-72.
15
16. Groheux D, Espié M, Giacchetti S, Hindié E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2 0 1 3 ; 2 6 6 ( 2 ) : 3 8 8 - 4 0 5 .
16
17. Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426-35.
17
18. Groheux D, Majdoub M, Sanna A, de Cremoux P, Hindié E, Giacchetti S, et al. Early metabolic response to neoadjuvant treatment: FDG PET/ CT criteria according to breast cancer subtype. Radiology. 2015;27:141638.
18
19. Cheng G, Torigian DA, Zhuang H, Alavi A. When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Med Mol Imaging. 2013;40(5):779-87.
19
ORIGINAL_ARTICLE
Value of Dedicated Head and Neck 18F-FDG PET/CT Protocol in Detecting Recurrent and Metastatic Lesions in Post-surgical Differentiated Thyroid Carcinoma Patients with High Serum Thyroglobulin Level and Negative 131I Whole-body Scan
Objective(s): In clinical practice, approximately 10-25% of post-surgical differentiated thyroid carcinoma (DTC) patients with high serum thyroglobulin (Tg) and negative 131I whole-body scan (WBS) have poor prognosis due to recurrent or metastatic lesions after radioactive iodine treatment. The purpose of this study was to evaluate the value of 18F-FDG PET/CT scan in DTC patients with high serum Tg level and negative 131I WBS.Methods: 69 post-surgical DTC patients with high serum Tg level and negative post ablation 131I WBS were enrolled in this study. All DTC patients underwent head and neck ultrasound, CT scan and whole-body 18F-FDG PET/CT, based on the dedicated head and neck protocol.Results: Overall, 92 lesions were detected in 43 (62.3%) out of 69 patients with positive 18F-FDG PET/CT scan, compared to only 39 lesions detected on CT scan in 26 (37.7%) out of 69 patients. The sensitivity, accuracy and negative predictive value of 18F-FDG PET/CT were 88%,87% and 76%, respectively, which were significantly higher than those of CT scan (67.2%, 54.3% and 48.8%, respectively) (P<0.01). Specificity and positive predictive value of 18F-FDG PET/CT (90.5% and 95.2%, respectively) were similar to those of CT scan (95.2 % and 96.2 %, respectively) (P>0.05). The maximum standardized uptake value (SUVmax) threshold was 4.5 with a good diagnostic value (sensitivity of 92.3 % and specificity of 100 %). The dedicated head and neck 18F-FDG PET/CT protocol altered the treatment plan in 33 (47.8%) out of 69 DTC patients with high serum Tg level and negative 131I WBS.Conclusion: Dedicated head and neck 18F-FDG PET/CT protocol showed a higher diagnostic value, compared to CT scan and played an important role in detecting recurrent or metastatic lesions in post-surgical DTC patients with high serum Tg level and negative 131I WBS.
https://aojnmb.mums.ac.ir/article_5670_7ef1c70457c2e02354061d78fdb2cec6.pdf
2016-01-01
12
18
10.7508/aojnmb.2016.04.003
18F-FDG PET/CT
Differentiated Thyroid Carcinoma
Head and neck
Thyroglobulin
Mai Hong
Son
hongsondhy@yahoo.com
1
Department of Nuclear Medicine, Tran Hung Dao Hospital, Hanoi, Vietnam
AUTHOR
Bui Quang
Bieu
buiquangbieu108@gmail.com
2
Department of Nuclear Medicine, Tran Hung Dao Hospital, Hanoi, Vietnam
AUTHOR
Le Ngoc
Ha
lengocha108@yahoo.com
3
Department of Nuclear Medicine, Tran Hung Dao Hospital, Hanoi, Vietnam
LEAD_AUTHOR
1. Bảo PTM, Hà LN. Experiences of I(131) therapy in differentiated thyroid carcinoma. Clin Med Oncol. 2006;2(1):30-7.
1
2. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-28.
2
3. Ha LN, Nhung NT, Son MH, Bieu BQ. Clinical characteristics and preliminary evaluation of empirical 131 I therapy in differentiated thyroid carcinoma patients with negative 131 I whole? Body scan and elevated serum thyroglobulin. J Clin Med Pharma. 2014;9(Special):92-9.
3
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.
4
5. Townsend DW, Cherry SR. Combining anatomy and function: the path to true image fusion. Eur Radiol. 2001;11(10):1968-74.
5
6. Blodgett TM, Ryan A, Akbarpouranbadr A, McCook BM. PET/CT protocols and artifacts in the head and neck. PET Clin. 2007;2(4):433-43.
6
7. Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181-200.
7
8. Wong TZ. Fras IM. PET/CT protocols and practical issues for the evaluation of patients with head and neck cancer. PET Clin. 2007;2(4):413–21.
8
9. Fleming ID, Cooper JS, Henson DE, Hutter VP, Kennedy BJ, Murphy GP, et al. American joint committee on cancer. AJCC Cancer Staging Manual. New York: Springer; 2010.
9
10. Som PM. Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. AJR Am J Roentgenol. 1992;158(5):961-9.
10
11. Bannas P, Derlin T, Groth M, Apostolova I, Adam G, Mester J, et al. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan? Ann Nucl Med. 2012;26(1):77-85.
11
12. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48(2):221-6.
12
13. Marcus C, Whitworth PW, Surasi DS, Pai SI, Subramaniam RM. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol. 2014;202(6):1316- 29.
13
14. Feine U, Lietzenmayer R, Hanke JP, Wohrle H, Muller-Schauenburg W. [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I]. Nuklearmedizin. 1995;34(4):127-34.
14
15. Yamamoto Y, Wong TZ, Turkington TG, Hawk TC, Coleman RE. Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies. Radiology. 2007;244(1):263-72.
15
16. Beyer T, Antoch G, Muller S, Egelhof T, Freudenberg LS, Debatin J, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med. 2004;45 (Suppl 1):25S-35S.
16
17. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001;42(1):71-6.
17
18. Na SJ, Yoo IeR, O JH, Lin C, Lin Q, Kim SH, et al. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level. Ann Nucl Med. 2012;26(1):26-34.
18
19. Townsend DW. Dual-modality imaging: combining anatomy and function. J Nucl Med. 2008;49(6):938- 55.
19
20. van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology. 1990;177(2):379-84.
20
21. Bertagna F, Bosio G, Biasiotto G, Rodella C, Puta E, Gabanelli S, et al. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med. 2009;34(11):756-61.
21
22. Rosario PW, de Faria S, Bicalho L, Alves MF, Borges MA, Purisch S, et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med. 2005;24(10):1385-9.
22
23. Nahas Z, Goldenberg D, Fakhry C, Ewertz M, Zeiger M, Ladenson PW, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope. 2005;115(2):237-43.
23
24. Ma C, Xie J, Kuang A. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results? J Nucl Med. 2005;46(7):1164-70.
24
ORIGINAL_ARTICLE
Preclinical Studies of 68Ga-DOTATOC: Biodistribution Assessment in Syrian Rats and Evaluation of Absorbed Dose in Human Organs
Objective(s): Gallium-68 DOTA-DPhe1-Tyr3-Octreotide (68Ga-DOTATOC) has been applied by several European centers for the treatment of a variety of human malignancies. Nevertheless, definitive dosimetric data are yet unavailable. According to the Society of Nuclear Medicine and Molecular Imaging, researchers are investigating the safety and efficacy of this radiotracer to meet Food and Drug Administration requirements. The aim of this study was to introduce the optimized procedure for 68Ga-DOTATOC preparation, using a novel germanium-68 (68Ge)/68Ga generator in Iran and evaluate the absorbed doses in numerous organs with high accuracy. Methods: The optimized conditions for preparing the radiolabeled complex were determined via several experiments by changing the ligand concentration, pH, temperature and incubation time. Radiochemical purity of the complex was assessed, using high-performance liquid chromatography and instant thin-layer chromatography. The absorbed dose of human organs was evaluated, based on biodistribution studies on Syrian rats via Radiation Absorbed Dose Assessment Resource Method. Results: 68Ga-DOTATOC was prepared with radiochemical purity of >98% and specific activity of 39.6 MBq/nmol. The complex demonstrated great stability at room temperature and in human serum at 37°C at least two hours after preparation. Significant uptake was observed in somatostatin receptor-positive tissues such as pancreatic and adrenal tissues (12.83 %ID/g and 0.91 %ID/g, respectively). Dose estimations in human organs showed that the pancreas, kidneys and adrenal glands received the maximum absorbed doses (0.105, 0.074 and 0.010 mGy/MBq, respectively). Also, the effective absorbed dose was estimated at 0.026 mSv/MBq for 68Ga-DOTATOC. Conclusion: The obtained results showed that 68Ga-DOTATOC can be considered as an effective agent for clinical PET imaging in Iran.
https://aojnmb.mums.ac.ir/article_5043_b29217573428f76bf346ae3167049791.pdf
2016-01-01
19
29
10.7508/aojnmb.2016.04.004
Ga-68
Octreotide
Internal Dosimetry
Somatostatin
mojdeh
naderi
hasan.usefnia@gmail.com
1
Department of Chemistry, University of Zanjan, Zanjan, Iran
AUTHOR
samaneh
zolghadri
szolghadri@aeoi.org.ir
2
Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
LEAD_AUTHOR
hassan
yousefnia
hyousefnia@aeoi.org.ir
3
Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
AUTHOR
ali
ramazani
s_zolghadri63@yahoo.com
4
Department of Chemistry, University of Zanjan, Zanjan, Iran
AUTHOR
amir reza
jalilian
ajalili@aeoi.org.ir
5
Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
AUTHOR
Fani M, Maecke HR. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging. 2012;39(1):11-30.
1
Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, et al. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 2002;29(2):147-57.
2
Jamous M, Haberkorn U, Mier W. Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases. Molecules. 2013;18(3):3379-409.
3
Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3] octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med. 1998;25(7):668-74.
4
Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol. 1992;43(1-3):27-35.
5
Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26(11):1439-47.
6
Van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47(10):1599-606.
7
Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54(3):364-72.
8
Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. 1994;35(3 Suppl):S1-4.
9
Ö berg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966-73.
10
Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, et al. Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy. Chem Eur J. 1999;5(7):1974-81.
11
Townsend DW, Valk PE, Maisey MN. Positron Emission Tomography: Basic Sciences. London: Springer-Verlag; 2005.
12
Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer. 2002;98(6):930-7.
13
Breeman WA, de Blois E, Chan HS, Konijnenberg M, Kwekkeboom DJ, Krenning EP. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011;41(4):314-21.
14
Sudbrock F, Fischer T, Zimmermanns B, Guliyev M, Dietlein M, Drzezga A, et al. Characterization of SnO2-based 68Ge/68Ga generators and 68Ga- DOTATATE preparations: radionuclide purity, radiochemical yield and long-term onstancy. EJNMMI Res. 2014;4(1):36.
15
Banerjee SR, Pomper MG. Clinical applications of Gallium-68. Appl Radiat Isotop. 2013;76:2–13.
16
Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga- DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34(10):1617-26.
17
Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, et al. Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET: a lesion-by-lesion analysis in patients. Ann Oncol. 2013; 24:13.
18
Mirzaei A, Jalilian AR, Aghanejad A, Mazidi M, Yousefnia H, Shabani G, et al. Preparation and evaluation of 68Ga-ECC as a PET renal imaging agent. Nucl Med Mol Imaging. 2015;49(3):208-16.
19
Aigner H, Bleise RA, Burns K, Campbell M, Currie LA, Danesi PR, et al. Quantifying uncertainty in nuclear analytical measurements. Vienna, Austria: International Atomaic Energy Agency; 2004.
20
Sparks RB, Aydogan B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. Oak Ridge Asso Univ; 1999;2(2):705–16.
21
Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Asia Oceania J Nucl Med Biol. 2016; 4(1) Phys. 2003;85(3):294-310.
22
Yousefnia H, Zolghadri S, Jalilian AR, Tajik M, Ghannadi-Maragheh M. Preliminary dosimetric evaluation of 166Ho-TTHMP for human based on biodistribution data in rats. Appl Radiat Isot. 2014;94:260-5.
23
Bevelacqua JJ. Internal dosimetry primer. Radiat Prot Manage. 2005;22(5):7-17.
24
Brenner DJ. Effective dose: a flawed concept that could and should be replaced. Br J Radiol. 2008;81(967):521–3.
25
ICRP Publication 103. The 2007 Recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;37(2-4):1-332.
26
Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. Differential uptake of (68)Ga- DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. Recent Results Cancer Res. 2013;194:353-71.
27
Luboldt W, Hartmann H, Wiedemann B, Zo¨phel K, Luboldt HJ. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTA PET/CT using the example of somatostatin receptor radionuclide therapy. Mol Imaging. 2010;9(6):351–8.
28
Velikyan I, Beyer GJ, Långström B. Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15(3):554-60.
29
Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007;48(10):1741-8.
30
Bauwens M, Chekol R, Vanbilloen H, Bormans G, Verbruggen A. Optimal buffer choice of the radiosynthesis of (68)Ga-Dotatoc for clinical application. Nucl Med Commun. 2010;31(8):753-8.
31
Menda Y, Ponto LL, Schultz MK, Zamba GK, Watkins GL, Bushnell DL, et al. Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors. Pancreas. 2013;42(6):937–43.
32
Soto-Montenegro ML, Peña-Zalbidea S, Mateos- Pérez JM, Oteo M, Romero E, Morcillo MA, et al. Meningiomas: a comparative study of 68Ga- DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice. PLoS One. 2014;9(11):e111624.
33
Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging. 2005;32(4):478-85.
34
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs). A service of the U.S. National Institutes of Health. Available at: URL: http://www.cancer.gov/clinicaltrials; 2015.
35
Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines For PET/ CT tumour imaging with 68Ga-DOTAconjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004-10.
36
Sandström M, Velikyan I, Garske-Román U, Sörensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54(10):1755-9.
37
Kesner AL, Hsueh WA, Czernin J, Padgett H, Phelps ME, Silverman DH. Radiation dose estimates for [18F]5-fluorouracil derived from PET-based and tissue-based methods in rats. Mol Imaging Biol. 2008;10(6):341-8.
38
Palm S, Enmon RM Jr, Matei C, Kolbert KS, Xu S, Zanzonico PB et al. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90) Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med. 2003;44(7):1148-55.
39
ICRP Publication 62: Radiological Protection in Biomedical Research. 1st ed. Ottawa: ICRP Publication; 1993. P. 22.
40
Walker R, Smith G, Stabin M. First report of measured human dosimetry with 68Ga-DOTATATE. J Nucl Med. 2012;53(Supple 1):1514.
41
ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals. Ottawa: ICRP Publication; 1988. P. 1-4.
42
ORIGINAL_ARTICLE
In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate
Objective(s):Lutetium-177 can be made with high specific activity and with no other isotopes of lutetium present, referred to as “No Carrier Added” (NCA) 177Lu. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate with NCA 177Lu (“NCA-LuTATE”) and used it in nearly 40 therapeutic administrations for subjects with neuroendocrine tumours or meningiomas. In this paper, we report on our initial studies on aspects of the biodistribution and dosimetry of NCA-LuTATE from gamma camera 2D whole body (WB) and quantitative 3D SPECT (qSPECT) 177Lu imaging. Methods: Thirteen patients received 39 NCA-LuTATE injections. Extensive WB planar and qSPECT imaging was acquired at approximately 0.5, 4, 24 and 96 h to permit estimates of clearance and radiation dose estimation using MIRD-based methodology (OLINDA-EXM). Results:The average amount of NCA-Lutate administered per cycle was 7839±520 MBq. Bi-exponential modelling of whole body clearance showed half lives for the fast & slow components of t½=2.1±0.6 h and t½=58.1±6.6 h respectively. The average effective dose to kidneys was 3.1±1.0 Gy per cycle. In eight patients completing all treatment cycles the average total dose to kidneys was 11.7±3.6 Gy. Conclusions: We have shown that NCA-LuTATE has an acceptable radiation safety profile and is a suitable alternative to Carrier-Added 177Lu formulations. The fast component of the radiopharmaceutical clearance was closely correlated with baseline renal glomerular filtration rate, and this had an impact on radiation dose to the kidneys. In addition, it has less radioactive waste issues and requires less peptide per treatment.
https://aojnmb.mums.ac.ir/article_6232_344a186dc72e3e66591be2d712627e40.pdf
2016-01-01
30
37
10.7508/aojnmb.2016.04.005
Radionuclide therapy
SPECT, lutetium-177
neuro-endocrine tumours
Dale
Bailey
dale.bailey@sydney.edu.au
1
Department of Nuclear Medicine Royal North Shore Hospital St Leonards 2065 Sydney, NSW , AUSTRALIA
LEAD_AUTHOR
Thomas
Hennessy
thomas.hennessy@sesiahs.health.nsw.gov.au
2
Department of Nuclear Medicine Prince of Wales Hospital Randwick 2031 NSW
AUTHOR
Kathy
Willowson
kathy.willowson@sydney.edu.au
3
Institute of Medical Physics University of Sydney Sydney 2006 NSW
AUTHOR
Eric
Henry
ehen9430@uni.sydney.edu.au
4
Institute of Medical Physics University of Sydney Sydney 2006 NSW
AUTHOR
David
Chan
dlhchan1@gmail.com
5
Department of Nuclear Medicine Royal North Shore Hospital St Leonards 2065 NSW
AUTHOR
Alireza
Aslani
aaslani@med.usyd.edu.au
6
Department of Nuclear Medicine Royal North Shore Hospital St Leonards 2065 NSW
AUTHOR
Paul
Roach
paul.roach@sydney.edu.au
7
Department of Nuclear Medicien Royal North Shore Hospital St Leonards 2065 NSW
AUTHOR
1. Bailey DL, Hennessy TM, Willowson KP, Henry EC, Chan DL, Aalani A, et al. In vivo quantification of (177)Lu with planar whole-body and SPECT/CT gamma camera imaging. EJNMMI Phys. 2015;2(1):20-36.
1
2. Aslani A, Snowdon G, Bailey D, Schembri G, Baily E, Pavlakis N, et al. Lutetium-177 DOTATATE production with an automated radiopharmaceutical synthesis system. Asia Ocean J Nucl Med Biol. 2015;3(2):107-15.
2
3. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28(9):1319-25.
3
4. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37S-61S.
4
5. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023-7.
5
6.Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37(3):538-46.
6
7. Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Wildstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33-41.
7
8. Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging. 2010;37(2):212-25.
8
9. Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36(7):1138-46.
9
10. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides. Q J Nucl Med Mol Imaging. 2006;50(4):288-95.
10
11. Wehrmann C, Senftleben S, Zachert C, Muller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22(3):406-16.
11
12. Limouris G, Paphiti MI, Moulopoulou L, McCready RV. Comparison and evaluation of nca and ca Lu-177-[DOTA (0), Tyr3] octreotate in (GEP-NETs) treated patients. Eur J Nucl Med Mol Imag. 2014;41(233):S551.
12
ORIGINAL_ARTICLE
Background-Based Delineation of Internal Tumor Volumes on Static Positron Emission Tomography in a Phantom Study
Objective(s): Considering the fact that the standardized uptake value (SUV) of a normal lung tissue is expressed as x±SD, x+3×SD could be considered as the threshold value to outline the internal tumor volume (ITV) of a lung neoplasm. Methods: Three hollow models were filled with 55.0 kBq/mL fluorine18- fluorodeoxyglucose (18F-FDG) to represent tumors. The models were fixed to a barrel filled with 5.9 kBq/mL 18F-FDG to characterize normal lung tissues as a phantom. The PET/CT images of the phantom were acquired at rest. Then, the barrel was moved periodically to simulate breathing while acquiring PET/CT data. Volume recovery coefficient (VRC) was applied to evaluate the accuracy of ITVs. For statistical analysis, paired t-test and analysis of variance were applied. Results: The VRCs ranged from 0.74 to 0.98 and significantly varied among gross tumor volumes for delineating ITV (P<0.01). In two-dimensional PET scans, the motion distance did not affect VRC (P>0.05), whereas VRC decreased with increasing distance in three-dimensional PET scans (P<0.05). Conclusion: The threshold value (x+3×SD) had the potential to delineate the ITV of cancerous tissues, surrounded by lung tissues, particularly in two-dimensional PET images.
https://aojnmb.mums.ac.ir/article_5341_82de523e76b190f9e1e61d6daf132d8d.pdf
2016-01-01
38
44
10.7508/aojnmb.2016.04.006
Gross tumor volume
internal tumor volume
Positron Emission Tomography
standardized uptake value
yangchun
chen
1526797743@qq.com
1
Department of Nuclear Medicine, Quanzhou First Hospital, Fujian Medical University, Quanzhou, China
LEAD_AUTHOR
Xiangrong
Chen
2310611338@qq.com
2
Department of Radiology, Quanzhou First Hospital, Fujian Medical University, Quanzhou, China
AUTHOR
Ji-an
Liu
13729809322@163.com
3
Guangdong Provincial Key Laboratory of Micro-nano Manufacturing Technology and Equipment, Guangdong University
of Technology, Guangzhou, China
AUTHOR
Fanyong
Li
lifanyong@126.com
4
The PET-CT Center, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
AUTHOR
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014;12(12):1738-61.
1
Apostolova I, Wiemker R, Paulus T, Kabus S, Dreilich T, van den Hoff J, et al. Combined correction of recovery effect and motion blur for SUV quantification of solitary pulmonary nodules in FDG PET/CT. Eur Radiol. 2010;20(8):1868-77.
2
Wang J, del Valle M, Goryawala M, Franquiz JM, McGoron AJ. Computer-assisted quantification of lung tumors in respiratory gated PET/CT images: phantom study. Med Biol Eng Comput. 2010;48(1):49-58.
3
Bundschuh RA, Martínez-Möller A, Essler M, Nekolla SG, Ziegler SI, Schwaiger M. Local motion correction for lung tumours in PET/CT--first results. Eur J Nucl Med Mol Imaging. 2008;35(11):1981-8.
4
Schaefer A, Kremp S, Hellwig D, Rube C, Kirsch CM, Nestle U. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging. 2008;35(11):1989-99.
5
Okubo M, Nishimura Y, Nakamatsu K, Okumura M, Shibata T, Kanamori S, et al. Static and moving phantom studies for radiation treatment planning in a positron emission tomography and computed tomography (PET/CT) system. Ann Nucl Med. 2008;22(7):579–86.
6
Riegel AC, Bucci MK, Mawlawi OR, Johnson V, Ahmad M, Sun X, et al. Target definition of moving lung tumors in positron emission tomography: correlation of optimal activity concentration thresholds with object size, motion extent, and source-to-background ratio. Med Phys. 2010;37(4): 1742-52.
7
Townsend DW. Dual-modality imaging: combining anatomy and function. J Nucl Med. 2008;49(6):938- 55.
8
Chen Y, Chen X, Ji-An L, Li F. Estimation of internal tumor volume: a phantom study based on semiautomatics standardized uptake value of the background. Chinese J Med Imaging. 2015;23:91-5.
9
Chen Y, Chen X, Li F, Ji-An L. Gross target volume delineation on PET images by a numerical approximation method–phantom studies. Nucl Electron Detect Technol. 2014;34:1463-8.
10
Chen Y, Chen X, Li F, Ji-An L. Delineation gross tumor volume based on positron emission tomography images by a numerical approximation method. Ann Nucl Med. 2014;28(10):980-5.
11
Meirelles GS, Kijewski P, Akhurst T. Correlation of PET/CT standardized uptake value measurements between dedicated workstations and a PACS-integrated workstation system. J Digit Imaging. 2007;20(3):307–13.
12
Townsend DW. Dual-modality imaging: combining anatomy and function. J Nucl Med. 2008;49(6):938- 55.
13
Chen Y, Zhang C, Xu H, Chen P, Fan M. Registered error between PET and CT images confirmed by a water model. Nucl Technique. 2012;35:619-23.
14
Park SJ, Ionascu D, Killoran J, Mamede M, Gerbaudo VH, Chin L, et al. Evaluation of the combined effects of target size, respiratory motion and background activity on 3D and 4D PET/CT images. Phys Med Biol. 2008;53(13):3661-79.
15
Fahey FH. Data acquisition in PET imaging. J Nucl Med Technol. 2002;30(2):39-49.
16
ORIGINAL_ARTICLE
Evaluation of the Effect of Tumor Position on Standardized Uptake Value Using Time-of-Flight Reconstruction and Point Spread Function
Objective(s): The present study was conducted to examine whether the standardized uptake value (SUV) may be affected by the spatial position of a lesion in the radial direction on positron emission tomography (PET) images, obtained via two methods based on time-of-flight (TOF) reconstruction and point spread function (PSF). Methods: A cylinder phantom with the sphere (30mm diameter), located in the center was used in this study. Fluorine-18 fluorodeoxyglucose (18F-FDG) concentrations of 5.3 kBq/ml and 21.2 kBq/ml were used for the background in the cylinder phantom and the central sphere respectively. By the use of TOF and PSF, SUVmax and SUVmean were determined while moving the phantom in a horizontal direction (X direction) from the center of field of view (FOV: 0 mm) at 50, 100, 150 and 200 mm positions, respectively. Furthermore, we examined 41 patients (23 male, 18 female, mean age: 68±11.2 years) with lymph node tumors , who had undergone 18F-FDG PET examinations. The distance of each lymph node from FOV center was measured, based on the clinical images. Results: As the distance of a lesion from the FOV center exceeded 100 mm, the value of SUVmax, which was obtained with the cylinder phantom, was overestimated, while SUVmean by TOF and/or PSF was underestimated. Based on the clinical examinations, the average volume of interest was 8.5 cm3. Concomitant use of PSF increased SUVmax and SUVmean by 27.9% and 2.8%, respectively. However, size of VOI and distance from the FOV center did not affect SUVmax or SUVmean in clinical examinations. Conclusion: The reliability of SUV quantification by TOF and/or PSF decreased, when the tumor was located at a 100 mm distance (or farther) from the center of FOV. In clinical examinations, if the lymph node was located within 100 mm distance from the center of FOV, SUV remained stable within a constantly increasing range by use of both TOF and PSF. We conclude that, use of both TOF and PSF may be helpful.
https://aojnmb.mums.ac.ir/article_6167_4f67d2ea4e6cb81761dedf9dc02f0d7f.pdf
2016-01-01
45
50
10.7508/aojnmb.2016.04.007
standardized uptake value
time-of-flight
point-spread-function
18F-FDG
tumor size
Yasuharu
Wakabayashi
wakachin@mbe.ocn.ne.jp
1
Division of Radiological Technology, Saitama Prefectural Cancer Center, Saitama, Japan
LEAD_AUTHOR
Kenichi
Kashikura
k.kashikura@gmail.com
2
Graduate School of Radiological Technology, Gunma Prefectural College of Health Sciences, Gunma, Japan
AUTHOR
Yasuyuki
Takahashi
mtaka0412@yahoo.co.jp
3
Graduate School of Radiological Technology, Gunma Prefectural College of Health Sciences, Gunma, Japan
AUTHOR
Hitoshi
Yabe
yabe.hitoshi@cancer-c.pref.saitama.jp
4
Division of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
AUTHOR
Akihiro
Ichikawa
a-ichikawa@cancer-c.pref.saitama.jp
5
Division of Molecular Imaging, Saitama Prefectural Cancer Center, Saitama, Japan
AUTHOR
Souichi
Yamamoto
yamamotos@cancer-c.pref.saitama.jp
6
Division of Radiological Technology, Saitama Prefectural Cancer Center, Saitama, Japan
AUTHOR
Ayumi
Ishii
chan.ishii@cancer-c.pref.saitama.jp
7
Division of Radiological Technology, Saitama Prefectural Cancer Center, Saitama, Japan
AUTHOR
Kunio
Doi
k-doi@uchicago.edu
8
Department of Radiology, University of Chicago, Chicago, Illinois, USA
AUTHOR
Ter-Pogossian MM, Phelps ME, Hoffman EJ, Mullani NA. A positron-emission transaxial tomography for nuclear imaging (PETT). Radiology. 1975;114(1):89-98.
1
Nutt R. 1999 ICP Distinguished Scientist Award. The history of positron emission tomography. Mol Imaging Biol. 2002;4(1):11-26.
2
Levin Klausen T, Hogild Keller S, Vinter Olesen O, Aznar M, Andersen FL. Innovation in PET/CT. Q J Nucl Med Mol Imaging. 2012;56(3):268-79.
3
Conti M. Focus on time-of-flight PET: the benefits of improved time resolution. Eur J Nucl Med Mol Imaging. 2011;38(6):1147-57.
4
Krishnamoorthy S, LeGeyt B, Werner ME, Kaul M, Newcomer FM, Karp JS, et al. Design and performance of a high spatial resolution, time-of-flight PET detector. IEEE Trans Nucl Sci. 2014;61(3):1092-8.
5
Ko GB, Lee JS. Performance characterization of high quantum efficiency metal package photomultiplier tubes for time-of-flight and high-resolution PET applications. Med Phys. 2015;42(1):510-20.
6
Kadmas DJ, Casey ME, Conti M, Jakoby BW, Lois C, Townsend DW. Impact of time-of flight on PET tumor detection. J Nucl Med. 2009;50(8):1315-23.
7
Schaefferkoetter J, Casey M, Townsend D, El Fakhri G. Clinical impact of time-of-flight and point response modeling in PET reconstructions: a lesion detection study. Phys Med Biol. 2013;58(5):1465-78.
8
Alongi P, Picchio M, Bettinardi V, Samanes AM, Landoni C, Orlandi G, et al. Impact of time-of-flight (TOF) and point-spread-function (PSF) PET on whole-body oncologic studies. J Nucl Med. 2012;53(Suppl 1):2344.
9
Lasnon C, Hicks RJ, Beauregard JM, Milner A, Paciencia M, Guizard AV, et al. Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer. Clin Nucl Med. 2012;37(10):971-6.
10
Akamatsu G, Mitsumoto K, Taniguchi T, Tsutsui Y, Baba S, Sasaki M. Influence of point-spread function and time-of-flight reconstructions on standardized uptake value of lymph node metastases in FDG-PET. Eur J Radiol. 2014;83(1):226-30.
11
Prieto E, Dominguez-Prado I, Garcia-Velloso MJ, Penuelas I, Richter JA, Marti-Climent JM. Impact of time-of-flight and point-spread-function in SUV quantification for oncological PET. Clin Nucl Med. 2013;38(2):103-9.
12
Bettinardi , Presotto L, Rapisarda E, Picchino M, Gianolli L, Gilardi MC. Physical performance of the new hybrid PET/CT Discovery-690. Med Phys. 2011;38(10):5394-411.
13
Okubo M, Nishimura Y, Nakamatsu K, Okumura M, Shibata T, Kanamori S, et al. Static and moving phantom studies for radiation treatment planning in a positron emission tomography and computed tomography (PET/CT) system. Ann Nucl Med. 2008;22(7):579-86.
14
Biehl KJ, Kong FM, Dehdashti F, Jin JY, Mutic S, El Naqa I, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med. 2006;47(11):1808-12.
15
Akamatsu G, Ishikawa K, Mitsumoto K, Taniguchi T, Ohya N, Baba S, et al. Improvement in PET/CT image quality with a combination of point-spread function and time-of-flight in relation to reconstruction parameters. J Nucl Med. 2012;53(11):1716-22.
16
Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicenter trials when using different generation PET system: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40(7):985-96.
17
Fukukita H, Senda M, Terauchi T, Suzuki K, Daisaki H. Matsumoto K, et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of version 1.0. Ann Nucl Med. 2010;24(4):325-34.
18
Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/ CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181-200.
19
Fukukita H, Suzuki K, Matsumoto K, Terauchi T, Daisaki H, Ikari Y, et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 2.0. Ann Nucl Med. 2014;28(7):693-705.
20
ORIGINAL_ARTICLE
Imaging of accidental contamination with F-18-solution; a quick trouble-shooting procedure
To the best of our knowledge, imaging of accidental exposure to radioactive fluorine-18 (F-18) due to liquid spill has not been described earlier in the scientific literature. The short half-life of F-18 (t½=110 min), current radiation safety requirements, and Good Manufacturing Practice (GMP) regulations on radiopharmaceuticals have restrained the occurrence of these incidents. The possibility of investigating this type of incidents by gamma and positron imaging is also quite limited. Additionally, a quick and precise analysis of radiochemical contamination is cumbersome and sometimes challenging if the spills of radioactive materials are low in activity. Herein, we report a case of accidental F-18 contamination in a service person during a routine cyclotron maintenance procedure. During target replacement, liquid F-18 was spilled on the person responsible for the maintenance. The activities of spills were immediately measured using contamination detectors, and the photon spectrum of contaminated clothes was assessed through gamma spectroscopy. Despite protective clothing, some skin areas were contaminated, which were then thoroughly washed. Later on, these areas were imaged, using positron emission tomography (PET), and a gamma camera (including spectroscopy). Two contaminated skin areas were located on the hand (9.7 and 14.7 cm2, respectively), which showed very low activities (19.0 and 22.8 kBq respectively at the time of incident). Based on the photon spectra, F-18 was confirmed as the main present radionuclide. PET imaging demonstrated the shape of these contaminated hot spots. However, the measured activities were very low due to the use of protective clothing. With prompt action and use of proper equipments at the time of incident, minimal radionuclide activities and their locations could be thoroughly analyzed. The cumulative skin doses of the contaminated regions were calculated at 1.52 and 2.00 mSv, respectively. In the follow-up, no skin changes were observed in the contaminated areas.
https://aojnmb.mums.ac.ir/article_6159_b0d80ad035cb1b1451c77a98f5c80ed5.pdf
2016-01-01
51
54
10.7508/aojnmb.2016.04.008
F-18
quantitative gamma imaging
radiofluorine uptake
radiopharmaceutical preparation
skin contamination
Kalevi
Kairemo
kalevi.kairemo@docrates.com
1
Department of Molecular Radiotherapy & Nuclear Medicine, Docrates Cancer Center, Helsinki, Finland
LEAD_AUTHOR
Aki
Kangasmäki
a.kangasmaki@docrates.com
2
Department of Radiation Physics, Docrates Cancer Center, Saukonpaadenranta, Helsinki, Finland
AUTHOR
Covens P, Berus D, Cavaliers V, Struelens L, Verellen D. Skin contamination of nuclear medicine technologists: incidence, routes, dosimetry and decontamination. Nucl Med Comm. 2012;33(10):1024-31.
1
Bixler A, Springe G, Lovas R. Practical aspects of radiation safety for using fluorine-18. J Nucl Med Technol. 1999;27(1):14-6.
2
Schleipman AR, Gerbaudo VH, Castronovo FP Jr. Radiation disaster response: preparation and simulation experience at an academic medical center. J Nucl Med Technol. 2004;32(1):22-7.
3
Hussain RP. Management of radioactive spills in nuclear medicine; teaching and assessing with objectively structured assessment of technical skills. World J Nucl Med. 2015;14(2):89-94.
4
Inoue Y, Asano Y, Satoh T, Tabata KI, Kikuchi K, Woodhams R, et al. Phase IIa clinical trial of Trans-1- amino-3-18F-fluoro-cyclobutane carboxylic acid in metastatic prostate cancer. Asia Oceania J Nucl Med Biol. 2014;2(2):87-94.
5
Kim JS, Park SY. Inflammatory pseudotumor in the epidural space of lumbosacral spine on 18F-FDG PET/CT. Asia Oceania J Nucl Med Biol. 2014;2(2):138-42.
6
Saha GB. Fundamentals of nuclear pharmacy. 2nd ed. New York: Springer Science Business Media; 1984. P. 238
7
Eckerman KF, Wolbarst AB, Richardson AC. Limiting values of radionuclide intake and air concentration and dose conversion factors for inhalation, submersion, and ingestion: Federal guidance report No. 11 (No. EPA- 520/1-88-020). Washington, DC: Office of Radiation Programs; Oak Ridge National Lab, TN (USA); 1988. P. 122-56.
8
Covens P, Berus D, Cavaliers V, Struelens L, Vanhavere F, Verellen D. Skin dose rate conversion factors after contamination with radiopharmaceuticals: influence of contamination area, epidermal thickness and percutaneous absorption. J Radial Prot. 2013;33(2):381-93.
9
Moore PH Jr, Mettler FA Jr. Skin decontamination of commonly used medical radionuclides. J Nucl Med. 1980;21(5):475-6.
10
Ruhman N, Grantham V, Martin C. The effectiveness of decontamination products in the nuclear medicine department. J Nucl Med Technol. 2010;38(4):191-4.
11
ORIGINAL_ARTICLE
History and Perspectives of Nuclear Medicine in Bangladesh
Bangladesh is one of the smaller states in Asia. But it has a long and rich history of nuclear medicine for over sixty years. The progress in science and technology is always challenging in a developing country. In 1958, work for the first Nuclear Medicine facility was commenced in Dhaka in a tin-shed known as ‘Radioisotope Centre’ and was officially inaugurated in 1962. Since the late 50s of the last century nuclear medicine in Bangladesh has significantly progressed through the years in its course of development, but still the facilities are inadequate. At present there are 20 nuclear medicine establishments with 3 PET-CTs, 42 gamma camera/SPECTs with 95 physicians, 20 physicists, 10 radiochemists and 150 technologists. The Society of Nuclear Medicine, Bangladesh (SNMB) was formed in 1993 and publishing its official journal since 1997. Bangladesh also has close relationships with many international organizations like IAEA, ARCCNM, AOFNMB, ASNM, WFNMB and WARMTH. The history and the present scenario of the status of nuclear medicine in Bangladesh are being described here.
https://aojnmb.mums.ac.ir/article_4989_577f28cd0d205c284aaa787b33d0b058.pdf
2016-01-01
55
58
10.7508/aojnmb.2016.04.009
History
Nuclear Medicine
Bangladesh
Raihan
Hussain
raihan_h@yahoo.com
1
National Institute of Nuclear Medicine and Allied Sciences, Dhaka, Bangladesh
LEAD_AUTHOR
1. Hasan M. Present, past and future of nuclear medicine in Bangladesh. Bangladesh J Nucl Med. 2014; 17(1):8-9.
1
2. Saha DK. Bangladesh Atomic Energy Commission. Annual Report. 2013;1.
2
3. Sabih D. The Asian Nuclear Medicine Board (ANMB); why do we need it? Asia J Nucl Med Biol.
3
2013;1(2):1-3.
4
4. Office Records Documents. National Institute of Nuclear medicine and Allied Sciences (NINMAS).
5
Available at: http://www.drdo.gov.in/drdo/labs/INMAS/English/index.jsp?pg=homebody.jsp; 2015.
6
5. Hussain R. Nuclear medicine in the region – Asiaoceania organisational perspective. Bangladesh J
7
Nucl Med. 2014;17(1):11-2.
8